Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.5591
-0.0505 (-8.28%)
At close: Apr 6, 2026, 4:00 PM EDT
0.5535
-0.0056 (-1.00%)
After-hours: Apr 6, 2026, 7:09 PM EDT
Ensysce Biosciences Employees
As of December 31, 2024, Ensysce Biosciences had 8 total employees, including 7 full-time and 1 part-time employees. The number of employees increased by 1 or 14.29% compared to the previous year.
Employees
8
Change (1Y)
1
Growth (1Y)
14.29%
Revenue / Employee
$633,331
Profits / Employee
-$1,271,963
Market Cap
5.19M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | 3 | - | - | 3 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 36 |
| BiomX | 20 |
| Cardio Diagnostics Holdings | 17 |
| Purple Biotech | 10 |
| XTL Biopharmaceuticals | 10 |
| Dermata Therapeutics | 8 |
| Artelo Biosciences | 7 |
| Ernexa Therapeutics | 7 |
ENSC News
- 7 days ago - Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results - Accesswire
- 4 weeks ago - Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans - Accesswire
- 4 weeks ago - Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology - Accesswire
- 5 weeks ago - Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review - Benzinga
- 5 weeks ago - Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value - Accesswire
- 6 weeks ago - Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events - Accesswire
- 2 months ago - Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain - Accesswire
- 2 months ago - Ensysce Biosciences Expands Global Opioid Patent Portfolio - Accesswire